Monday, 17 November 2014

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Empagliflozin tablets reduced hemoglobin A1C, body weight and several markers of abdominal fat in adults with type 2 diabetes, according to a new retrospective analysis of clinical trial data presented on behalf of Boehringer Ingelheim and Eli Lilly at the 2014 Scientific Sessions of the American Heart Association in Chicago


VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study

The investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN® (ezetimibe/simvastatin) – which combines simvastatin with the non-statin ZETIA® (ezetimibe) -- experienced significantly fewer major cardiovascular events than patients treated with simvastatin alone (Merck)


Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies

Treatment with ACE/ARBs results in significant reduction in CV events and mortality in hypertensive patients with T2 DM (BMC Cardiovascular Disorders)


All-cause mortality and estimated renal function in type 2 diabetes mellitus outpatients: Is there a relationship with the equation used?

In our cohort of T2DM outpatients, different eGFR equations perform similarly in predicting ACM, whereas SCr did not (Diabetes and Vascular Disease Research)

No comments:

Post a Comment